Douglas Holtzman

Douglas Holtzman, Ph.D., M.P.H. is the Chief Scientific Officer (CSO) of Icosavax. He has more than 25 years of experience in industry and the philanthropic sector leading and funding innovative research and development activities with an emphasis on vaccines. Prior to Icosavax, he was Vice President, Discovery at Takeda Pharmaceuticals, where he led a team working on dengue and norovirus vaccine candidates. He was also a member of the management committee that helped to globalize Takeda’s Japan-based vaccines business. Prior to Takeda, Doug was Deputy Director, Childhood Pneumonia, at the Bill & Melinda Gates Foundation, where he developed strategies to tackle the global burden of childhood pneumonia, including RSV, through novel vaccine and vaccination programs and increased access to care. He received his Ph.D. in molecular and cell biology from UC Berkeley and his public health training from the Harvard T.H. Chan School of Public Health.